Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Targeting the Bcl-2 family for cancer therapy.

Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB.

Expert Opin Ther Targets. 2013 Jan;17(1):61-75. doi: 10.1517/14728222.2013.733001. Epub 2012 Nov 22. Review.

2.

Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.

Hartman ML, Czyz M.

Anticancer Agents Med Chem. 2012 Oct 1;12(8):966-81. Review.

PMID:
22263800
3.

Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.

Bajwa N, Liao C, Nikolovska-Coleska Z.

Expert Opin Ther Pat. 2012 Jan;22(1):37-55. doi: 10.1517/13543776.2012.644274. Epub 2011 Dec 23. Review.

4.

Targeting the Bcl-2.

Patel MP, Masood A, Patel PS, Chanan-Khan AA.

Curr Opin Oncol. 2009 Nov;21(6):516-23. doi: 10.1097/CCO.0b013e328331a7a4. Review.

PMID:
19730103
5.

Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.

Yu L, Liu S.

Semin Cancer Biol. 2013 Dec;23(6 Pt B):553-60. doi: 10.1016/j.semcancer.2013.08.008. Epub 2013 Sep 4. Review.

6.

Emerging Bcl-2 inhibitors for the treatment of cancer.

Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH.

Expert Opin Emerg Drugs. 2011 Mar;16(1):59-70. doi: 10.1517/14728214.2010.515210. Epub 2010 Sep 3. Review.

7.

Targeting Mcl-1 for the therapy of cancer.

Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, Wu B, Stebbins JL, Reed JC, Pellecchia M, Sarkar D, Fisher PB.

Expert Opin Investig Drugs. 2011 Oct;20(10):1397-411. doi: 10.1517/13543784.2011.609167. Epub 2011 Aug 19. Review.

8.
9.

Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.

Vela L, Marzo I.

Curr Opin Pharmacol. 2015 Aug;23:74-81. doi: 10.1016/j.coph.2015.05.014. Epub 2015 Jun 14. Review.

PMID:
26079328
10.

Bcl-2 inhibitors: emerging drugs in cancer therapy.

Bodur C, Basaga H.

Curr Med Chem. 2012;19(12):1804-20. Review.

PMID:
22414090
11.

Therapeutic inhibition of BCL-2 and related family members.

Levy MA, Claxton DF.

Expert Opin Investig Drugs. 2017 Mar;26(3):293-301. doi: 10.1080/13543784.2017.1290078. Epub 2017 Feb 9. Review.

PMID:
28161988
12.

Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.

Richardson A, Kaye SB.

Curr Mol Pharmacol. 2008 Nov;1(3):244-54. Review.

PMID:
20021437
13.

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Kang MH, Reynolds CP.

Clin Cancer Res. 2009 Feb 15;15(4):1126-32. doi: 10.1158/1078-0432.CCR-08-0144. Review.

14.

Mimicking the BH3 domain to kill cancer cells.

Ni Chonghaile T, Letai A.

Oncogene. 2008 Dec;27 Suppl 1:S149-57. doi: 10.1038/onc.2009.52. Review.

15.

BH3 mimetics to improve cancer therapy; mechanisms and examples.

Zhang L, Ming L, Yu J.

Drug Resist Updat. 2007 Dec;10(6):207-17. Epub 2007 Oct 24. Review.

16.

Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Davids MS, Letai A.

J Clin Oncol. 2012 Sep 1;30(25):3127-35. doi: 10.1200/JCO.2011.37.0981. Epub 2012 May 29. Review.

17.

Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

Scarfò L, Ghia P.

Immunol Lett. 2013 Sep-Oct;155(1-2):36-9. doi: 10.1016/j.imlet.2013.09.015. Epub 2013 Oct 1. Review.

PMID:
24095849
18.
19.

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.

Straten Pt, Andersen MH.

Oncotarget. 2010 Aug;1(4):239-45. Review.

20.

Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.

Karnak D, Xu L.

Curr Drug Targets. 2010 Jun;11(6):699-707. Review.

Supplemental Content

Support Center